City-based healthcare player, Cadila Healthcare (Zydus Cadila), has reported 140 per cent jump in standalone net profit for the second quarter ended September 30, 2014 at Rs 365 crore compared with Rs 152 crore in the same quarter previous year.
The company's standalone total income increased from Rs 994 crore to Rs 1,396 crore for the quarter ended September 30, 2014, Cadila Healthcare informed in a statement filed with the stock exchanges on Thursday.
On a consolidated basis, the company’s net profit jumped 52 per cent to Rs 278 crore during the quarter from Rs 183 crore in the corresponding quarter of the previous year.
The company’s consolidated total income increased 21 per cent during the quarter to Rs 2108 crore from Rs 1747 crore in the same period previous year.
Cadila Healthcare's UK business registered sales of Rs 802 crore showing a growth of 68 per cent during the quarter.
Cadila Healthcare shares ended positive on Wednesday at Rs 1416.30 on the Bombay Stock Exchange (BSE) ahead of the financial results announcement on Thursday.
For the US market, Zydus has received approval for 6 new products from the US drug regulator, USFDA and 4 products were launched in the US market, the company informed in a statement issued on Thursday.